Neumora Therapeutics' Experimental Drug Demonstrates Weight Loss In Preclinical Studies

2025-10-27 08:13:39

(MENAFN- AsiaNet News)

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.
The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.

Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.

The company said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice. Semaglutide is the active ingredient in Novo Nordisk's popular weight-loss drug Wegovy.

Plans Ahead

The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.

Shares of the company jumped about 22% in the pre-market session at the time of writing.

Get updates to this developing story <directly on Stocktwits.

MENAFN27102025007385015968ID1110252667

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.